Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 0.85 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PDE1A | P54750 | 1/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | DHPS | P49366 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278414 | 1.00 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7272788 | 0.92 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL9078544 | 0.87 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7281912 | 0.86 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL7271255 | 0.85 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL7279910 | 0.85 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL7271311 | 0.85 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7278584 | 0.85 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7278375 | 0.85 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7280079 | 0.84 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | BT BIDCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116726362-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116726361-A | Methods and devices for treating diseases with biologic therapeutic agents | 比奥拉治疗股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| CN-113348011-B | Method and apparatus for treating disease with biotherapeutic agents | 比奥拉治疗股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2023-01-26 | — | — | US | disclosed |
| US-11439802-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2022-09-13 | — | — | US | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | PDE4A, PDE1A, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 12/4885 |
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | PDE4A 1732/4885PDE4B 1756/4885PDE4C 2120/4885 |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | PDE4A 531/4885PDE4B 594/4885PDE4C 682/4885 |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | HAVCR2, CD47, FCGR3B | PDE4A 3181/4885PDE4B 3135/4885PDE4C 2436/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | PDE4A 2161/4885PDE4B 2370/4885PDE4C 2054/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | PDE4A 1096/4885PDE4B 985/4885PDE4C 1021/4885 |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | PDE4A 2034/4885PDE4B 2522/4885PDE4C 1742/4885 |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | MUC1, SLC10A2, FABP2 | PDE4A 531/4885PDE4B 594/4885PDE4C 682/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | PDE4A 2404/4885PDE4B 2753/4885PDE4C 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.